Browse Documents
by Date or Issue:
  • Trump main topic at Schrader town hall
    Posted in Schrader in the News on February 22, 2017 | Preview rr

    Members of Congress returned to their districts this week to hear from their constituents. Democrat U.S. Rep. Kurt Schrader drew a friendly crowd at his town hall Tuesday night. Hundreds of people turned out for his first town hall meeting under the new president. And President Donald Trump was the main topic of conversation. Schrader is in a mixed district politically, and Republicans are said to be targeting his seat in 2018. But the four-term congressman said he’s used to it. “Well, that’s pr... Read more

  • Rep. Kurt Schrader Calls President Donald Trump's Border Wall "A Stupid Idea"
    Posted in Schrader in the News on January 27, 2017 | Preview rr
    Tags: Budget, Deficit Reduction & Fiscal Reform, National Defense, Immigration, Trade

    On Wednesday, President Donald Trump announced plans to follow through with his campaign pledge to add to the existing wall between the U.S. and Mexico, at a cost of around $15 billion. U.S. Rep. Kurt Schrader (D-Ore.)'s tweet this morning is pretty self-explanatory. Schrader represents Oregon's Fifth District, which covers a wide swath of the Willamette Valley, where agricultural interests depend on immigrant labor, and the parts of the Cascades and the Coast Range, where migrant workers often... Read more

  • Six Oregon lawmakers oppose Trump's EPA grant freeze
    Posted in Schrader in the News on January 25, 2017 | Preview rr
    Tags: Agriculture, Energy & Environment, Forestry & Natural Resources

    WASHINGTON - Six Oregon lawmakers, all Democrats, told the White House on Wednesday that its decision to freeze grants administered by the Environmental Protection Agency poses a serious threat to fundamental public health and environmental protections in Oregon and nationwide. "Americans deserve to know whether the EPA will protect their health and safety and defend their communities from air, land, and water contamination,'' said the letter to the president from Sens. Ron Wyden and Jeff Merkle... Read more

  • Oregon's congressional Democrats call on Trump to unfreeze EPA funds
    Posted in Schrader in the News on January 25, 2017 | Preview rr

    Oregon's congressional Democrats sent a letter to President Donald J. Trump on Wednesday, calling on him to unfreeze Environmental Protection Agency contracts and grants, while also asking the president to allow agency staff to speak with the media and respond to Congressional inquiries. U.S. Sens. Ron Wyden and Jeff Merkley signed the letter, along with U.S. Reps. Kurt Schrader, Earl Blumenauer, Suzanne Bonamici and Peter DeFazio. Republican U.S. Rep. Greg Walden did not sign the letter. The me... Read more

  • Trump at Odds With His VA Nominee on Hiring Freeze
    Posted in Schrader in the News on January 25, 2017 | Preview rr
    Tags: Veterans

    President Donald Trump's hiring freeze at the Department of Veterans Affairs appeared to put him at odds with his own nominee to head the VA, Dr. David Shulkin. Shulkin, currently chief executive of the Veterans Health Administration, has repeatedly cited the need to hire more caregivers at the VA to cut wait times. In addition, the acting head of the VA, Robert Snyder, said Tuesday that he was looking for ways around the Trump freeze. "The Department of Veterans Affairs intends to exempt anyone... Read more

  • Schrader Wants to Speed Up Approval Time for Generic Drugs
    Posted in Schrader in the News on October 26, 2016 | Preview rr
    Tags: Healthcare Resources Center

    The Lower Drug Costs Through Competition Act would give the FDA six months to approve generic drugs, for which a brand name version of the active drug has already been authorized. The bill has bipartisan support, and he believes it could be passed as part of the year-end negotiations in President Obama’s lame-duck session. U.S. Rep. Kurt Schrader has introduced legislation with bipartisan support that he believes will limit pharmaceutical profiteering and encourage manufacturers to produce gener... Read more

  • Schrader Bill to Speed Development of Generic Drugs Gains Momentum
    Posted in Schrader in the News on September 23, 2016 | Preview rr

    A bill to encourage faster development of generic drugs has picked up 13 co-sponsors since the pricing controversy over anti-allergy EpiPen auto-injectors erupted, prompting its sponsor to hope it passes this year. “The more we wait, the more they’ll rip off the consumer,” Rep. Kurt Schrader, D-Ore., said Friday. Schrader introduced the bill with Rep. Gus Bilirakis, R-Fla., in March in response to Turing Pharmaceutical’s decision to raise the price of Daraprim, used to treat life-threatening tox... Read more

  • Rep. Schrader on The Mark Mason Show on KPAM 860
    Posted in Schrader in the News on September 7, 2016 | Preview rr

    Click here to listen to the interview. Mark Mason: Joining us now is Congressman Kurt Schrader from the 5th congressional district welcome back to the Mark Mason show sir. Congressman Kurt Schrader: Hey thanks Mark. MM: We’ve had a lot of talk in the last few weeks about EpiPens and the price spikes and the makers of epi pen saying that you know what were we going to put out a generic version, or at least a less expensive version, this is something though you have seen coming for a long time, I ... Read more

  • EpiPen Price Hike Gives New Life To Oregonian's Pharmaceutical Bill
    Posted in Schrader in the News on September 2, 2016 | Preview rr

    Oregon Congressman Kurt Schrader says headlines about spiraling drug prices have lent new life to his bill that would control medication costs. Early this year, Schrader sponsored a bill to encourage competition between generic drug companies, but it didn’t get anywhere. The idea was to prevent price hiking by people like pharmaceutical executive Martin Shkreli. He gained international attention after he obtained the manufacturing license for an anti-parasitic drug and raised the price more than... Read more

  • Upset Continues Over Mylan’s EpiPen Price Hike
    Posted in Schrader in the News on September 2, 2016 | Preview rr

    The price of the EpiPen has skyrocketed nearly 500% in the last few years, and with no alternatives available, parents are turning to the internet to find cheaper options. The EpiPen is a device that injects epinephrine to reverse allergic reactions from hives and itching to other, potentially deadly reactions. While health care experts are urging parents not to buy alternatives online, Mylan, the only company that makes the drug, says it will finally develop a generic version after coming under... Read more